AU2003210923A1 - Compositions and methods for promoting lipid mobilization, glycogen mobilization, or both, in humans - Google Patents

Compositions and methods for promoting lipid mobilization, glycogen mobilization, or both, in humans Download PDF

Info

Publication number
AU2003210923A1
AU2003210923A1 AU2003210923A AU2003210923A AU2003210923A1 AU 2003210923 A1 AU2003210923 A1 AU 2003210923A1 AU 2003210923 A AU2003210923 A AU 2003210923A AU 2003210923 A AU2003210923 A AU 2003210923A AU 2003210923 A1 AU2003210923 A1 AU 2003210923A1
Authority
AU
Australia
Prior art keywords
residue
xaa
amino acid
human
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003210923A
Other languages
English (en)
Inventor
Bernice Z Schacter
Lee P Schacter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BLM Group
Original Assignee
BLM Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BLM Group filed Critical BLM Group
Publication of AU2003210923A1 publication Critical patent/AU2003210923A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
AU2003210923A 2002-02-07 2003-02-07 Compositions and methods for promoting lipid mobilization, glycogen mobilization, or both, in humans Abandoned AU2003210923A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/072,419 US6852693B2 (en) 2002-02-07 2002-02-07 Compositions and methods for promoting lipid mobilization in humans
US10/072,419 2002-02-07
PCT/US2003/003800 WO2003066080A1 (en) 2002-02-07 2003-02-07 Compositions and methods for promoting lipid mobilization, glycogen mobilization, or both, in humans

Publications (1)

Publication Number Publication Date
AU2003210923A1 true AU2003210923A1 (en) 2003-09-02

Family

ID=27732307

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003210923A Abandoned AU2003210923A1 (en) 2002-02-07 2003-02-07 Compositions and methods for promoting lipid mobilization, glycogen mobilization, or both, in humans

Country Status (7)

Country Link
US (3) US6852693B2 (https=)
EP (1) EP1480668A1 (https=)
JP (1) JP2005516996A (https=)
AU (1) AU2003210923A1 (https=)
CA (1) CA2474203A1 (https=)
WO (1) WO2003066080A1 (https=)
ZA (1) ZA200406715B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852693B2 (en) 2002-02-07 2005-02-08 Blm Group Compositions and methods for promoting lipid mobilization in humans
US20050214275A1 (en) * 2004-01-02 2005-09-29 Gross Richard W Sequential ordered fatty acid alpha oxidation and delta9 desaturation are major determinants of lipid storage and utilization in adipocytes
US20050222040A1 (en) * 2004-04-05 2005-10-06 Blm Group, Inc. Vertebrate peptide modulators of lipid metabolism
JP4688483B2 (ja) * 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
WO2010051347A1 (en) * 2008-10-31 2010-05-06 David Sheikh-Hamad A method for cardioprotection
AU2010210600B2 (en) * 2009-02-06 2016-07-14 C3 Jian, Inc. Calcium-binding agents induce hair growth and/or nail growth
EP3119416B1 (en) 2015-03-26 2017-12-20 Mutlu, Oguz Therapeutic use of adipokinetic hormone/red pigment-concentrating hormone (akh/rpch) family of peptides
TR201712479A2 (tr) 2017-08-22 2019-05-21 Oguz Mutlu Adi̇poki̇neti̇k hormon/kirmizi pi̇gment-konsantre edi̇ci̇ hormon (akh/rpch) pepti̇t ai̇lesi̇ni̇n yeni̇ terapöti̇k kullanimlari
KR102380291B1 (ko) * 2020-06-15 2022-03-29 대한민국 풀무치 추출물을 포함하는 비만 예방 또는 치료용 조성물
KR102380290B1 (ko) * 2020-06-15 2022-03-29 대한민국 아메리카왕거저리 유충 추출물을 포함하는 비만 예방 또는 치료용 조성물
GB202215797D0 (en) 2022-10-25 2022-12-07 Solasta Bio Ltd Insect neuropeptide analogues
US12281143B1 (en) 2023-10-23 2025-04-22 Solasta Bio Limited Insect neuropeptides 1
US12279621B1 (en) 2023-10-23 2025-04-22 Solasta Bio Limited Insect neuropeptides 3
US12356995B2 (en) 2023-10-23 2025-07-15 Solasta Bio Limited Insect neuropeptides 9
US12245596B1 (en) 2023-10-23 2025-03-11 Solasta Bio Limited Insect neuropeptides 8
US12302908B2 (en) 2023-10-23 2025-05-20 Solasta Bio Limited Insect neuropeptides 4
US12245588B1 (en) 2023-10-23 2025-03-11 Solasta Bio Limited Insect neuropeptides 2
EP4570072A3 (en) * 2023-10-23 2025-07-02 Solasta Bio Limited Insect neuropeptides 8

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260601A (en) 1979-10-23 1981-04-07 Nyegaard & Co. A/S Chemical compounds
US4328134A (en) 1980-05-06 1982-05-04 Schally Andrew Victor Anorexigenic peptides
US4464356A (en) 1982-05-07 1984-08-07 Mordes John P Anorexigenic composition and method
US4489059A (en) 1982-05-07 1984-12-18 Rossini Aldo A Anorexigenic composition and method
US4891219A (en) 1986-03-14 1990-01-02 Aphton Corporation Method for immunization against and treatment of infection by ectoparasites and endoparasites
GB8806471D0 (en) 1988-03-18 1988-04-20 Tisdale M J Biologically active material characterised by catabolic activity generally associated with cachexia inducing tumours
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
FR2710340B1 (fr) 1993-09-22 1995-12-15 D Hinterland Lucien Dussourd Dérivés peptidiques de l'alpha-MSH et leur application .
FR2767135B1 (fr) 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
US6852693B2 (en) * 2002-02-07 2005-02-08 Blm Group Compositions and methods for promoting lipid mobilization in humans

Also Published As

Publication number Publication date
US20040224898A1 (en) 2004-11-11
US7314865B2 (en) 2008-01-01
JP2005516996A (ja) 2005-06-09
WO2003066080A1 (en) 2003-08-14
CA2474203A1 (en) 2003-08-14
US8067363B2 (en) 2011-11-29
US20090036383A1 (en) 2009-02-05
EP1480668A1 (en) 2004-12-01
US6852693B2 (en) 2005-02-08
US20030162717A1 (en) 2003-08-28
ZA200406715B (en) 2006-06-28

Similar Documents

Publication Publication Date Title
US8067363B2 (en) Compositions and methods for promoting lipid mobilization in humans
US5912227A (en) Method of enhancing nutrient uptake
JP5792925B2 (ja) 過剰体重を防止または治療するためのオキシンソモジュリン
Boatright et al. Regulation of endogenous dopamine release in amphibian retina by melatonin: the role of GABA
JP2019104768A (ja) 代謝性症候群を予防し又は治療するための方法
JPH10330397A (ja) サイトカイン調節剤およびサイトカインレベルの変化に関連する病状および状態における使用方法
CN103403023A (zh) 细胞凋亡抑制剂及其用途
JP2003518477A (ja) 反応性酸素種およびフリーラジカルの効力を中和するための組成物および方法
JPH07502971A (ja) 改良された血糖隆下剤
WO2016134215A1 (en) Methods of treating mild brain injury and post-traumatic stress disorder
WO2008143835A1 (en) Ghrelin protects substantia nigra dopamine neurons
JP2013535965A (ja) 鎮痛作用とａｓｉｃチャンネルを阻害する新規ペプチド
JP6716187B2 (ja) アディポネクチン受容体に対する作用薬ペプチド
US9155778B2 (en) Tripeptides that down regulate the activity of plasma membrane transporters including sodium-D-glucose cotransporter SgIt1
EP3158995B1 (en) Meglumine for reducing high triglyceride levels
Claye et al. Both dynorphin A (1-17)[Des-Tyr1] dynorphin A (2-17) inhibit adenylyl cyclase activity in rat caudate putamen.
US10105414B2 (en) Peptides derived from RS1 which down-regulate glucose absorption after a glucose rich meal and increase insulin sensitivity
US20240285723A1 (en) Combination compositions for the treatment of pathogen infections and associated complications
US10894811B2 (en) Peptide inhibitors of calcium channels
KR102118116B1 (ko) Foxp3 또는 이를 코딩하는 유전자를 포함하는 나노입자 및 이의 용도
US20200206302A1 (en) Use of des-aspartate-angiotensin i to treat patients exhibiting inflammatory diseases and their symptoms
US9840547B2 (en) Hepatic insulin sensitizing substance and test meal for insulin sensitization
JPH06510753A (ja) インスリン欠乏哺乳動物治療用のインスリンおよびアミリンを含有する組成物
EP1705256A1 (en) Methods for the treatment of insulin resistance and disease states characterized by insulin resistance
EP2033656A1 (en) Satiety-modulating compositions for oral application

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application